2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Non-Biological Therapies, Anticoagulant Drugs, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Immunology, Infectious Diseases, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Study Population, Human, Adult, Pediatric
PAPER

4839 Lower longitudinal ADAMTS13 activity does not explain reduced coronary perfusion in ittp survivors

Krishna Doshi, MD, Madhumahita Maddukuri2, Spero R Cataland, MD3, Senthil Sukumar, MD,MSc4
1 UT Health San Antonio School of Medicine, San Antonio, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States
3 Ohio State University, Columbus, Ohio, United States
4 Baylor College of Medicine, Houston, Texas, United States

Background: Survivors of immune-mediated thrombotic thrombocytopenic purpura (iTTP) experience substantial cardiovascular morbidity during clinical remission, with major adverse cardiovascular events reported in 23.8% of a prior cohort. We previously demonstrated reduced myocardial perfusion reserve (MPR) in iTTP survivors as compared with matched controls (median 2.63 vs 3.67; p=0.005). Although reduced remission ADAMTS13 activity has been associated with stroke after iTTP, we did not demonstrate an association between remission ADAMTS13 activity and composite cardiovascular events. Therefore, we investigated whether longitudinal ADAMTS13 activity was associated with MPR in iTTP survivors.

Methods: We performed a secondary analysis of iTTP survivors who underwent adenosine stress cardiac magnetic resonance (CMR) imaging as part of our prospective CMR study. Global MPR was analyzed as a continuous outcome. Longitudinal ADAMTS13 measurements obtained on or before each patient’s CMR date were used to calculate time-weighted ADAMTS13 activity by trapezoidal integration. Results reported as undetectable or <10% were assigned 0% in the primary analysis and 5% or 9.9% in sensitivity analyses. The primary cohort included patients with iTTP, usable MPR, and at least two distinct ADAMTS13 measurement dates. The association between time-weighted ADAMTS13 and MPR was assessed primarily using Spearman rank correlation. Kendall correlation and linear regression were performed as secondary analyses.

Results: Twelve iTTP survivors had sufficient MPR and longitudinal ADAMTS13 data. Time-weighted activity was estimable in 10 patients; two patients had only one measurement on or before CMR and were excluded from the primary analysis. All 10 patients were female, with a median age of 47 years. Median MPR was 2.67 (IQR, 2.23–3.12), and median time-weighted ADAMTS13 activity was 63.6% (IQR, 45.9%–66.9%). Patients had a median of 32 distinct ADAMTS13 measurement dates spanning 6.9 years. Time-weighted ADAMTS13 was not significantly associated with MPR in the primary analysis (Spearman ρ=−0.588; p=0.074). The inverse coefficient indicates that higher longitudinal ADAMTS13 activity tended to accompany lower, rather than higher, MPR. Kendall correlation was also directionally consistent (τ=−0.467; p=0.074). In linear regression, each 10-percentage-point increase in time-weighted ADAMTS13 was associated with a 0.24-unit lower MPR, although the confidence interval included no association (95% CI, −0.57 to 0.08; p=0.119). Assigning undetectable measurements values of 5% or 9.9% also showed the inverse direction without producing a statistically significant association.

Conclusions: Longitudinal ADAMTS13 activity was not significantly associated with MPR in this small cohort of iTTP survivors. Although the observed relationship was inverse, these findings should not be interpreted as evidence that higher ADAMTS13 activity is detrimental or contributes to endothelial injury. Rather, the consistently inverse direction across analyses suggests that higher remission ADAMTS13 activity is not necessarily accompanied by better myocardial perfusion reserve and that recovery of ADAMTS13 alone may not reflect normalization of cardiac microvascular health. Post-iTTP cardiac microvascular dysfunction may instead reflect prior acute microvascular injury, persistent inflammation, endothelial dysfunction, or other cardiovascular risk factors not captured by remission ADAMTS13 activity. Larger multicenter studies are needed to determine whether the inverse pattern represents biological heterogeneity, residual confounding, or small-sample variation.

Krishna Doshi, MD: No relevant conflicts of interest to declare.